BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

9441 related articles for article (PubMed ID: 19068467)

  • 1. [Examination of different factors influencing the vascularization of human cutaneous melanoma].
    Kiss J
    Magy Onkol; 2008 Dec; 52(4):385-9. PubMed ID: 19068467
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of microvessel density with infiltrating cells in human cutaneous malignant melanoma.
    Kiss J; Tímár J; Somlai B; Gilde K; Fejôs Z; Gaudi I; Ladányi A
    Pathol Oncol Res; 2007; 13(1):21-31. PubMed ID: 17387385
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hyperforin acts as an angiogenesis inhibitor.
    Schempp CM; Kiss J; Kirkin V; Averbeck M; Simon-Haarhaus B; Kremer B; Termeer CC; Sleeman J; Simon JC
    Planta Med; 2005 Nov; 71(11):999-1004. PubMed ID: 16320199
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hyperforin and aristoforin inhibit lymphatic endothelial cell proliferation in vitro and suppress tumor-induced lymphangiogenesis in vivo.
    Rothley M; Schmid A; Thiele W; Schacht V; Plaumann D; Gartner M; Yektaoglu A; Bruyère F; Noël A; Giannis A; Sleeman JP
    Int J Cancer; 2009 Jul; 125(1):34-42. PubMed ID: 19326439
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of tumour cell growth by hyperforin, a novel anticancer drug from St. John's wort that acts by induction of apoptosis.
    Schempp CM; Kirkin V; Simon-Haarhaus B; Kersten A; Kiss J; Termeer CC; Gilb B; Kaufmann T; Borner C; Sleeman JP; Simon JC
    Oncogene; 2002 Feb; 21(8):1242-50. PubMed ID: 11850844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hyperforin, a bio-active compound of St. John's Wort, is a new inhibitor of angiogenesis targeting several key steps of the process.
    Martínez-Poveda B; Quesada AR; Medina MA
    Int J Cancer; 2005 Dec; 117(5):775-80. PubMed ID: 15981212
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hyperforin: more than an antidepressant bioactive compound?
    Medina MA; Martínez-Poveda B; Amores-Sánchez MI; Quesada AR
    Life Sci; 2006 Jun; 79(2):105-11. PubMed ID: 16438991
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aristoforin, a novel stable derivative of hyperforin, is a potent anticancer agent.
    Gartner M; Müller T; Simon JC; Giannis A; Sleeman JP
    Chembiochem; 2005 Jan; 6(1):171-7. PubMed ID: 15593112
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tetrahydrohyperforin and octahydrohyperforin are two new potent inhibitors of angiogenesis.
    Martínez-Poveda B; Verotta L; Bombardelli E; Quesada AR; Medina MA
    PLoS One; 2010 Mar; 5(3):e9558. PubMed ID: 20224821
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanisms of Hyperforin as an anti-angiogenic angioprevention agent.
    Lorusso G; Vannini N; Sogno I; Generoso L; Garbisa S; Noonan DM; Albini A
    Eur J Cancer; 2009 May; 45(8):1474-84. PubMed ID: 19223175
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD73 on B16F10 melanoma cells in CD73-deficient mice promotes tumor growth, angiogenesis, neovascularization, macrophage infiltration and metastasis.
    Koszałka P; Gołuńska M; Stanisławowski M; Urban A; Stasiłojć G; Majewski M; Wierzbicki P; Składanowski AC; Bigda J
    Int J Biochem Cell Biol; 2015 Dec; 69():1-10. PubMed ID: 26545615
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic impact of B-cell density in cutaneous melanoma.
    Ladányi A; Kiss J; Mohos A; Somlai B; Liszkay G; Gilde K; Fejös Z; Gaudi I; Dobos J; Tímár J
    Cancer Immunol Immunother; 2011 Dec; 60(12):1729-38. PubMed ID: 21779876
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hyperforin, a new lead compound against the progression of cancer and leukemia?
    Quiney C; Billard C; Salanoubat C; Fourneron JD; Kolb JP
    Leukemia; 2006 Sep; 20(9):1519-25. PubMed ID: 16791262
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imiquimod inhibits melanoma development by promoting pDC cytotoxic functions and impeding tumor vascularization.
    Aspord C; Tramcourt L; Leloup C; Molens JP; Leccia MT; Charles J; Plumas J
    J Invest Dermatol; 2014 Oct; 134(10):2551-2561. PubMed ID: 24751730
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expresson of vascular endothelial growth factor, its receptors (FLT-1, KDR) and TSP-1 related to microvessel density and patient outcome in vertical growth phase melanomas.
    Straume O; Akslen LA
    Am J Pathol; 2001 Jul; 159(1):223-35. PubMed ID: 11438469
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Density of DC-LAMP(+) mature dendritic cells in combination with activated T lymphocytes infiltrating primary cutaneous melanoma is a strong independent prognostic factor.
    Ladányi A; Kiss J; Somlai B; Gilde K; Fejos Z; Mohos A; Gaudi I; Tímár J
    Cancer Immunol Immunother; 2007 Sep; 56(9):1459-69. PubMed ID: 17279413
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry.
    Maniotis AJ; Folberg R; Hess A; Seftor EA; Gardner LM; Pe'er J; Trent JM; Meltzer PS; Hendrix MJ
    Am J Pathol; 1999 Sep; 155(3):739-52. PubMed ID: 10487832
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Microcirculation and tumor-infiltrating macrophages in choroidal and ciliary body melanoma and corresponding metastases.
    Toivonen P; Mäkitie T; Kujala E; Kivelä T
    Invest Ophthalmol Vis Sci; 2004 Jan; 45(1):1-6. PubMed ID: 14691146
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The changes of angiogenesis and immune cell infiltration in the intra- and peri-tumoral melanoma microenvironment.
    Zidlik V; Brychtova S; Uvirova M; Ziak D; Dvorackova J
    Int J Mol Sci; 2015 Apr; 16(4):7876-89. PubMed ID: 25913374
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hyperforin inhibits MMP-9 secretion by B-CLL cells and microtubule formation by endothelial cells.
    Quiney C; Billard C; Mirshahi P; Fourneron JD; Kolb JP
    Leukemia; 2006 Apr; 20(4):583-9. PubMed ID: 16467866
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 473.